FDA: Pradaxa not for patients with mechanical heart valves

December 21, 2012
FDA: pradaxa not for patients with mechanical heart valves
Pradaxa (dabigatran etexilate mesylate) should not be used to prevent stroke or blood clots (major thromboembolic events) in patients with mechanical heart valves, according to a Dec. 19 safety announcement issued by the U.S. Food and Drug Administration.

(HealthDay)—The blood thinner Pradaxa should not be used to prevent stroke or blood clots in patients with mechanical heart valves, the U.S. Food and Drug Administration said in a warning issued Wednesday.

As the agency noted, a clinical trial in Europe was halted recently because patients taking Pradaxa (dabigatran) were more likely to suffer strokes, heart attacks and clots forming on their mechanical heart valves than patients who were taking the older blood thinner warfarin.

Patients in the study who were taking Pradaxa also had more bleeding after valve surgery, the agency said.

Doctors should immediately switch patients with a mechanical heart valve who are taking Pradaxa to another medication, the FDA said. The use of Pradaxa in patients with heart valve replacements made of natural biological tissue has not been evaluated and cannot be recommended, the agency added.

The message for patients is that anyone who has received any type of heart valve replacement and is taking Pradaxa should talk to their doctor as soon as possible to determine the most appropriate type of blood thinner (anticoagulant) to take, the FDA said.

Consultation with a physician is crucial, agency officials said, because stopping anticoagulant drugs without seeking advice from their doctor first can increase the risk of blood clots and stroke.

Pradaxa is approved to treat patients with a common heart rhythm disorder called atrial fibrillation. It is not approved to treat patients with atrial fibrillation caused by heart valve problems, the FDA said.

One expert noted another problem with Pradaxa.

"Pradaxa belongs to a class of anticoagulants known as direct-thrombin inhibitors, and while these class of drugs have shown both promise and usefulness in clinical practice, there remains a significant downside, namely there is no "antidote" to this medication [as there is for example with Coumadin]," said Dr. Abe DeAnda, an associate professor in the department of cardiothoracic surgery at NYU Langone Medical Center. "Additionally, surveillance of the effectiveness of the medication and the systemic effect is more difficult to monitor and thus more difficult to titrate. I think that eventually we will move away from Coumadin as our drug of choice, but we are not at that point yet."

Explore further: FDA favors innovative heart valve for the frail

More information: More Information

Related Stories

FDA favors innovative heart valve for the frail

July 18, 2011

The first artificial heart valve designed to be implanted without major surgery appears to help patients who are too frail to undergo chest-opening surgery, according to federal health reviewers.

Easy-to-use blood thinners likely to replace Coumadin

February 6, 2012

Within a few years, a new generation of easy-to-use blood-thinning drugs will likely replace Coumadin for patients with irregular heartbeats who are at risk for stroke, according to a journal article by Loyola University ...

Anti-clot drug recommended for new approval in EU

September 21, 2012

(AP)—Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or blood clots, drugmakers Bristol-Myers ...

Recommended for you

What powers the pumping heart?

September 25, 2015

Researchers at the Ted Rogers Centre for Heart Research have uncovered a treasure trove of proteins, which hold answers about how our heart pumps—a phenomenon known as contractility.

Sticky gel helps stem cells heal rat hearts

September 24, 2015

A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and restore their metabolism after transplantation, improving cardiac function after simulated heart attacks, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.